Deconstructing Medtronic's 2026 M&A Playbook

Nelson Advisors
45 minutes ago
13 min read

Capital Allocation and Category Leadership: Deconstructing Medtronic's 2026 M&A Playbook

The corporate landscape for Medtronic plc in 2026 is defined by a significant transition from operational stabilization to aggressive capital allocation. Under the leadership of Chairman and Chief Executive Officer Geoff Martha and Chief Financial Officer Thierry Piéton, the medical technology giant has pivoted toward an offensive mergers and acquisitions strategy.

This strategic shift is designed to address public investor concerns regarding slow top-line growth and margin compression while actively positioning the company in high-growth, near-commercialisation clinical markets. Geoff Martha brings extensive transactional experience to this current campaign, having previously led Strategy and Business Development in 2011 and spearheaded the landmark forty-three billion dollar acquisition of Covidien in 2015.

This accelerated deal-making environment was initiated by structural governance reforms enacted in August 2025 in partnership with activist investor Elliott Investment Management L.P.. Following constructive dialogue with the activist firm, Medtronic expanded its board of directors to include John Groetelaars, the former Chief Executive Officer of Hillrom, and Bill Jellison, the former Chief Financial Officer of Stryker Corporation. Both independent directors brought decades of financial and operational medical technology expertise to the board.

Furthermore, the board established two specialized committees to align corporate governance with shareholder value creation initiatives. The newly formed Growth Committee, chaired by Geoff Martha, assumed responsibility for portfolio management, research and development capital allocation, divestitures, and growth-accretive strategic acquisitions.Concurrently, the Operating Committee was established to optimise global manufacturing, streamline supply chain logistics, implement expense management protocols, and drive margin expansion.

To optimise its capital structure and sharpen its strategic focus, Medtronic accelerated its portfolio simplification program through the structured divestiture of underperforming or non-core business segments. A primary example of this realignment was the separation of the MiniMed diabetes division via a Nasdaq initial public offering. Priced at twenty dollars per share for twenty-eight million shares, the MiniMed Group IPO closed on March 9th, 2026, raising seven hundred and eighty-four million dollars in gross proceeds and establishing a market valuation of approximately $7.86 Billion dollars.

While Medtronic retained substantial control over MiniMed by holding over eighty-eight percent of the post-IPO voting power, the transaction successfully carved out the lower-margin diabetes division. This structural carve-out stands in contrast to previous transaction attempts, such as the proposed seven hundred and thirty-eight million dollar acquisition of South Korean insulin patch pump developer EOFlow, which was permanently scrapped after that company became entangled in a complex patent and trade secrets dispute with Omnipod manufacturer Insulet.

Core Restructuring and Operational Consolidation

To support its financial algorithm and fund its aggressive pipeline expansion, Medtronic has implemented a sweeping operational restructuring program alongside its transactional activity. The company announced the phased closure of its long-standing manufacturing and development facility in Santa Rosa, California, which had operated since the 1998 acquisition of Arterial Vascular Engineering. This facility closure is reported to impact approximately three hundred and seventy on-site, hybrid, and remote employees. The operational phase-out is scheduled to begin in the spring of 2027, with a complete shutdown projected by the spring of 2028. The vascular and aortic work previously performed at the Santa Rosa campus is being transferred to consolidated manufacturing hubs in Santa Ana, California, Minnesota, and Galway, Ireland.

This consolidation is paired with an organizational realignment designed to break down internal commercial silos and simplify sales engagement with consolidated hospital purchasing groups. Medtronic combined its legacy Structural Heart, Coronary, and Renal Denervation businesses into a unified Interventional Cardiology Therapies operating unit.Simultaneously, the company consolidated its Cardiac Surgery and Aortic divisions into a newly formed Cardiovascular Surgery Operating Unit under the leadership of Karim Bandali, following the departure of Simona Zannetti who previously led the Aortic business. This dual-division structure allows Medtronic to offer comprehensive, integrated product lines that span surgery, diagnostics, interventional therapies, and post-operative care.

Deconstructing the 2026 M&A Portfolio

During the first five months of 2026, Medtronic announced three major acquisitions totaling approximately $1.78 Billion dollars in upfront cash and potential earn-outs. These transactions target distinct, high-growth clinical markets across the company's Neuroscience and Cardiovascular portfolios.

Target Company	Transaction Value	Announcement / Close Date	Primary Technology Platform	Target Business Unit	Core Clinical Objective
CathWorks	Up to $585 Million	Announced: Feb 3, 2026 Closed: Apr 20, 2026	FFRangio System (AI-powered, wire-free coronary physiology)	Interventional Cardiology Therapies	Displace invasive, wire-based fractional flow reserve diagnostics.
Scientia Vascular	$550 Million (plus earn-outs)	Announced: Mar 10, 2026 Expected Close: H1 FY2027	Microfabricated steerable guidewires and microcatheters	Neurovascular (Neuroscience Portfolio)	Improve navigability through complex cerebral anatomy in stroke.
SPR Therapeutics	~$650 Million (all-cash upfront)	Announced: May 20, 2026 Expected Close: H1 FY2027	SPRINT Peripheral Nerve Stimulation (PNS) System	Neuromodulation (Neuroscience Portfolio)	Expand early-intervention non-opioid, non-surgical pain options.

CathWorks: Transitioning to AI-Driven, Wire-Free Coronary Diagnostics

The acquisition of CathWorks for up to five hundred and eighty-five million dollars represents a core diagnostic expansion within the newly reorganised Interventional Cardiology Therapies unit. The central asset acquired is the FFRangio System, which combines artificial intelligence and advanced computational science to deliver a comprehensive physiological assessment of the entire coronary tree. Traditional fractional flow reserve (FFR) diagnostic procedures are highly invasive, requiring clinicians to thread specialized pressure wires into the coronary arteries and administer hyperemic drugs like adenosine to stimulate maximum blood flow. FFRangio eliminates these clinical requirements by obtaining precise, real-time FFR values directly from routine, drug-free and wire-free coronary angiograms.

The commercial expansion of this system is supported by clinical trial data. At the 2026 American College of Cardiology conference, CathWorks presented one-year outcomes from its landmark ALL-RISE randomised controlled trial. The trial enrolled more than 1,900 patients across fifty-nine clinical sites globally, demonstrating that the FFRangio system is non-inferior to traditional wire-based physiology regarding major adverse cardiac events (MACE) at one year. Additionally, the study showed significant improvements in resource utilization and a reduction in total procedure times.

The final acquisition closed on April 20th, 2026, marking the culmination of a multi-year partnership. Medtronic had held a minority investment in CathWorks since 2018, expanding the relationship in July 2022 with a seventy-five million dollar strategic investment and co-promotion agreement. Under this co-promotion partnership, global clinical utilisation of FFRangio expanded from one thousand patients to more than one hundred thousand. Post-acquisition, Medtronic plans to retain CathWorks' offices in Newport Beach, California (which expanded from Irvine in 2024), Israel and Japan, alongside all one hundred employees.

Scientia Vascular: Marrying Access and Therapeutics in Neurovascular Care

In the neurovascular stroke treatment segment, procedural efficiency is a primary driver of clinical outcomes. Medtronic's March 10th, 2026 agreement to acquire Scientia Vascular for five hundred and fifty million dollars in cash is designed to address navigation challenges within complex and tortuous cerebral vasculature.

Founded in Reno, Nevada in 2007 by Chief Technology Officer John Lippert, Scientia relocated to Salt Lake City, Utah in 2013 and expanded its manufacturing footprint in 2022 to meet rising clinical demand for its FDA-cleared devices. The company secured fifty million dollars in equity financing from Vivo Capital in 2021 and received its first FDA clearance in 2018. Scientia has developed a proprietary microfabrication technology that produces high-performance steerable microwires and microcatheters. These access tools allow interventionalists to navigate highly tortuous anatomy to reach the sites of occlusions or aneurysms quickly.

The integration of Scientia's access technologies with Medtronic's existing therapeutic neurovascular devices, such as mechanical thrombectomy stent retrievers and aspiration systems, provides a complete, end-to-end procedural workflow for both ischemic and hemorrhagic stroke care. The transaction is expected to close in the first half of Medtronic's fiscal year 2027. Corporate leadership expects the deal to be minimally dilutive to adjusted earnings per share in fiscal year 2027 and accretive thereafter.

SPR Therapeutics: Early-Intervention Neuromodulation for Chronic Pain

On May 20th, 2026, Medtronic announced its intent to acquire SPR Therapeutics, a privately held medical technology company specialising in temporary, percutaneous peripheral nerve stimulation (PNS) therapies. The transaction involves an upfront cash consideration of approximately six hundred and fifty million dollars for all outstanding equity.

SPR Therapeutics developed the SPRINT PNS System, which received FDA clearance in 2018 and achieved a milestone of fifty thousand clinical implants by the end of 2025. Unlike traditional neuromodulation systems that require the surgical implantation of permanent leads and pulse generators, SPRINT is a temporary, sixty-day therapy. It uses a fine lead placed percutaneously near a target peripheral nerve, connected to an external wearable generator to deliver short-term stimulation designed to recondition the central nervous system for sustained pain relief.

Domenico De Paolis, the interim president of Medtronic's Neuromodulation business, noted that the addition of a temporary PNS platform allows pain specialists to intervene much earlier in the patient care continuum. This early-intervention capability targets chronic pain patients who are seeking non-surgical, non-opioid options but are not yet candidates for permanent spinal cord stimulation or targeted drug delivery systems. Supported by clinical data from the RESET randomised controlled trial for chronic low back pain, the acquisition is expected to close in the first half of fiscal year 2027. It is structured to be minimally dilutive to adjusted EPS in fiscal year 2027 and neutral to accretive thereafter.

The Medtronic M&A Playbook: Programmatic Capital Allocation

The execution of these three transactions reveals a consistent, repeatable M&A playbook. This methodology is characterised by specific financial constraints, operational risk-mitigation strategies, and a focus on procedural integration.

Rather than executing high-risk, multi-billion-dollar mergers, Medtronic focuses on disciplined, programmatic "tuck-in" acquisitions within high-growth categories close to commercialisation. This playbook relies on a progressive incubation strategy, which often begins with a minority venture capital stake through Medtronic Ventures. This initial investment is typically followed by a commercial distribution or co-promotion partnership that includes a structured option-to-buy agreement. This pathway allows Medtronic to leverage its extensive global sales force to scale the technology, validate its clinical performance and assess physician adoption before deploying significant capital to buy the remaining equity.

This structured model is demonstrated by Medtronic's historical acquisitions. In 2016, Medtronic made an initial equity investment in Mazor Robotics, followed by an exclusive global distribution agreement for the Mazor X spine guidance platform in August 2017. Once commercial adoption was validated, Medtronic completed a $1.64 Billion dollar acquisition of the remaining outstanding shares in December 2018. The acquisition of CathWorks followed an identical structure, progressing from an initial minority investment in 2018 to a co-promotion partnership and seventy-five million dollar investment in 2022, and culminating in the five hundred and eighty-five million dollar acquisition in 2026.

Financially, the playbook is constrained by strict capital allocation guidelines. The target deal size is typically kept in the low-to-mid single-digit billion-dollar range, specifically between five hundred million and one billion dollars. These transactions are structured to remain immaterial or minimally dilutive to adjusted earnings per share in the first fiscal year, becoming neutral to accretive by the second or third year.

Operationally, the playbook prioritises procedural integration over simple revenue consolidation. Rather than purchasing generic revenue, Medtronic targets specific enabling technologies, software platforms and microfabricated devices that can be integrated into broader clinical ecosystems to drive recurring consumable pull-through. This approach is demonstrated by the AiBLE spine ecosystem, which combines Mazor robotic hardware, UNiD AI-driven surgical planning software, intra-operative navigation and spinal implants into a unified clinical offering. By establishing these comprehensive procedural ecosystems, Medtronic creates high switching costs, simplifies hospital procurement, and secures long-term commercial relationships.

Future Acquisition Targets: Predictive Analysis

By applying the parameters of Medtronic's documented M&A playbook to its active partnerships, minority investments and joint venture portfolios, three high-probability acquisition targets emerge.

Anteris Technologies: Structural Heart and TAVR Core Expansion

Anteris Technologies is currently the highest-probability acquisition target in Medtronic’s structural heart pipeline. On January 20th, 2026, Medtronic’s affiliate Covidien executed a highly structured ninety million dollar strategic investment to acquire a 16.2 % equity stake in the company, purchasing 15,652,173 shares of common stock at a price of $5.75 per share using Covidien's cash on hand. The investment was executed immediately after Anteris completed a public offering of common stock, which ultimately raised three hundred and twenty million dollars in gross proceeds to support research on its structural heart technologies. Medtronic's final ownership stake is capped between sixteen percent and 19.99 % under the terms of the stock purchase agreement.

The transaction is governed by an Investor Rights Agreement that contains specific provisions matching Medtronic's pre-acquisition playbook :

Notice and Negotiation Rights: If Anteris receives a third-party acquisition proposal, the agreement obligates the company to notify Covidien and grant it notice and negotiation rights, effectively acting as a defensive shield to prevent a competitor from acquiring the asset.
Standstill and Board Representation: The agreement establishes a customary standstill provision through May 22nd, 2027, during which Medtronic has the right to designate one non-voting observer to the Anteris board of directors.
Registration and Participation Rights: Covidien was granted registration rights for the resale of its shares and participation rights in certain future equity issuances to maintain its ownership percentage.

Anteris is developing the DurAVR Transcatheter Heart Valve (THV) System, a biomimetic aortic valve constructed from a single piece of patented, anti-calcification ADAPT tissue designed to mimic the hemodynamics of a healthy human aortic valve. In November 2025, the FDA approved the global PARADIGM trial to enroll approximately one thousand patients across the United States, Europe, and Canada to study the valve's safety and clinical performance. This clinical pathway provides the milestone framework required for Medtronic to exercise an acquisition buyout.

Integrating Anteris into its structural heart portfolio would allow Medtronic to complement its legacy self-expanding Evolut platform with a next-generation, balloon-expandable platform. This expanded offering would strengthen Medtronic's competitive position against Edwards Lifesciences and Abbott Laboratories.

Pulnovo Medical: Pulmonary Artery Denervation Integration

In April 2026, Medtronic led an oversubscribed one hundred million dollar strategic financing round for Pulnovo Medical, a pioneer in catheter-based therapies for pulmonary hypertension and heart failure. Medtronic was joined in this funding round by other major institutional investors, including EQT, Qiming Venture Partners, Gaorong Ventures, OrbiMed, Lilly Asia Ventures and HSG, formerly known as Sequoia China. Alongside this equity investment, Medtronic and Pulnovo entered into a commercial agreement to explore global commercialisation opportunities, leveraging Pulnovo's clinical technology alongside Medtronic's extensive international commercialisation infrastructure.

Pulnovo has developed the Pulmonary Artery Denervation (PADN) System, a first-in-class, minimally invasive device that delivers radiofrequency energy to the sympathetic nerves in the outer membrane of the pulmonary artery. This procedure disrupts overactive sympathetic nerve signals that contribute to pulmonary vascular remodeling and cardiopulmonary disease progression. PADN is supported by fifteen years of research and development, including clinical trials such as PADN-CFDA and PADN-5, and has received the FDA's Breakthrough Device designation. The company has initiated two fully approved Investigational Device Exemption trials in the United States, including the PULSE-LHD trial led by Dr. Gregg Stone at Mount Sinai.

This partnership fits the "Partner-to-Buy" model. Medtronic can leverage its existing interventional cardiology commercial teams and its established clinical expertise in renal denervation (using the Symplicity Spyral platform) to scale Pulnovo's technology. As clinical trials in the United States, Europe, and Asia approach completion, Pulnovo represents a highly logical acquisition candidate to strengthen Medtronic's presence in the interventional cardiovascular market.

Basivertebral Nerve Ablation: Interventional Pain Management Expansion

The interventional pain management market is experiencing rapid growth, driven by the expansion of basivertebral nerve ablation (BVNA) for the treatment of chronic vertebrogenic lower-back pain caused by damage to the vertebral endplates.On March 24, 2026, Medtronic entered into an exclusive strategic distribution agreement with Merit Medical Systems, Inc. to commercialise the newly FDA-cleared ViaVerte BVNA system.

ViaVerte is a minimally invasive, implant-free system that targets chronic pain by using radiofrequency energy to ablate the basivertebral nerve. It is the first and only BVNA system to feature a physician-controlled steerable mechanism, allowing for highly precise targeting of the basivertebral nerve. The distribution agreement builds on a long-standing business relationship, as Merit currently supplies Medtronic with Kyphon inflation syringes and steerable balloon catheters used in vertebral compression fracture treatments.

The BVNA segment is highly competitive. Boston Scientific acquired Relievant Medsystems for approximately eight hundred and fifty million dollars in late 2023 to secure the Intracept system, which has been used to treat fifty thousand patients of an estimated five million in the United States living with vertebrogenic pain. Stryker also entered the space in May 2025, receiving FDA clearance for its OptaBlate BVN system.

While the current distribution deal allows Medtronic to enter the market without deploying significant upfront capital, its documented playbook suggests a logical next step. If clinical adoption of the ViaVerte system scales successfully, Medtronic is highly likely to either acquire the ViaVerte technology asset outright from Merit Medical (which operates primarily as a diversified OEM supplier) or target other private, specialized BVNA developers to establish direct ownership of its therapeutic platforms in this segment.

Target Company	Stake / Deal Structure	Underlying Technology	Core Strategic Portfolio	Strategic Rationale
Anteris Technologies	16.2% strategic equity stake via Covidien ($90M)	DurAVR THV (biomimetic balloon-expandable aortic valve)	Structural Heart (Cardiovascular)	Secure a next-generation balloon-expandable valve platform to complement the Evolut self-expanding franchise.
Pulnovo Medical	Led oversubscribed $100M strategic round with commercial deal	PADN System (radiofrequency pulmonary artery denervation)	Interventional Cardiology (Cardiovascular)	Leverage renal denervation expertise to address pulmonary hypertension and heart failure via existing sales channels.
ViaVerte / Private BVNA	Exclusive distribution agreement with Merit Medical	ViaVerte BVNA (steerable basivertebral nerve ablation)	Neuromodulation (Neuroscience Portfolio)	Establish immediate commercial presence to compete against Boston Scientific and Stryker, with path to asset buyout.

Conclusions

The governance reforms enacted in late 2025 have established a highly disciplined, efficient capital allocation framework at Medtronic. Under the oversight of the Growth and Operating Committees, corporate leadership has successfully transitioned from a period of operational consolidation to an offensive M&A posture. The acquisitions of CathWorks, Scientia Vascular, and SPR Therapeutics demonstrate this strategic alignment, targeting high-growth, minimally invasive, and software-enabled categories to drive long-term value.

To maintain this positive momentum, Medtronic's corporate development teams must focus on the seamless integration of these newly acquired technologies. This includes expanding the commercial reach of the CathWorks FFRangio system by leveraging Medtronic’s global interventional cardiology sales force, and marrying Scientia's access catheters with existing therapeutic stroke devices to offer complete procedural workflows. Simultaneously, the integration of SPR's SPRINT system into the Neuromodulation division must be structured to engage pain patients earlier in their care continuum, creating a long-term referral pipeline for the company's permanent neuromodulation therapies.

Looking forward, Medtronic must continue to monitor its strategic investments and partnership portfolios. Strategic assets like Anteris Technologies and Pulnovo Medical represent highly logical acquisition candidates as they approach critical clinical trial milestones. At the upcoming mid-2026 Investor Day, the Growth and Operating Committees are scheduled to formally present their comprehensive portfolio recommendations and strategic roadmap. This milestone event will provide the public markets with a clear outlook on Medtronic's simplified corporate structure, its programmatic M&A pipeline, and its long-term financial algorithm.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech